Related Experiment Video
Updated: Aug 28, 2025

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA
1Liver Disease Branch, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
Insights
A new PCR assay can now differentiate hepatitis B surface antigen (HBsAg) sources. This tool helps understand integrated HBV DNA
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Chronic hepatitis B virus (HBV) infection is a significant global health concern.
- Hepatitis B surface antigen (HBsAg) loss signifies a functional cure for HBV.
- Covalently closed circular DNA (cccDNA) and integrated HBV DNA (iDNA) are key sources of HBsAg, with cccDNA predominant in HBeAg-positive and iDNA in HBeAg-negative patients.
Purpose of the Study:
- To develop a method distinguishing HBsAg sources (cccDNA vs. iDNA).
- To assess the contribution of different HBsAg sources in patients receiving nucleos(t)ide analog antivirals.
- To provide a tool for evaluating novel therapies aimed at a functional HBV cure.
Main Methods:
- Development of a polymerase chain reaction (PCR)-based assay.
- Differentiation of HBsAg originating from cccDNA versus iDNA.
- Analysis of HBsAg sources in patients undergoing antiviral therapy.
Main Results:
- A novel PCR assay successfully differentiated HBsAg sources.
- The study explored the relative contributions of cccDNA and iDNA to HBsAg production.
- Findings provide insights into HBsAg origins in patients on nucleos(t)ide analogs.
Conclusions:
- A new assay enables distinction between cccDNA and iDNA as HBsAg sources.
- Understanding iDNA's role is crucial for achieving a functional HBV cure.
- This tool can guide the development of targeted therapies for HBV functional cure.
Abstract:
Chronic hepatitis B virus (HBV) infection remains a major global health problem. Hepatitis B surface antigen (HBsAg) loss has been accepted as the definition of a functional HBV cure. Recent studies found that while covalently closed circular DNA (cccDNA) is the predominant source of HBsAg in hepatitis B e antigen-positive (HBeAg-positive) patients, integrated HBV DNA (iDNA) is the main source in HBeAg-negative patients. Consequently, achieving a functional HBV cure will require not only silencing of cccDNA but also iDNA. Assays that distinguish the source of HBsAg are needed to evaluate emerging therapies. In this issue of the JCI, Grudda et al. developed a PCR-based assay that differentiated the source of HBsAg and explored the contributing sources of HBsAg in patients on nucleos(t)ide analog antivirals. These findings provide a tool for understanding the contribution of iDNA in HBV infection and may guide therapies toward a functional HBV cure.
Related Concept Videos
Viruses with RNA Genomes
Size and Structure of Viral Genomes

